Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06017388
Other study ID # 2022-213
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date January 31, 2025

Study information

Verified date December 2023
Source University of Liege
Contact Aminata Bicego
Phone +3243663499
Email abicego@uliege.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mystical experience is described as an experience that is unique to everyone, potentially transformative and leaving a mark for many years or even a lifetime. It is characterized by: a loss of self/ego, being with the whole/nature/universe, transcendence, a loss of spatio-temporal reference points, ineffability, peace and joy, a sacred character, and a noetic quality. The mystical experience is one that occurs in the context of non-ordinary states of consciousness such as meditation and the consumption of so-called psychedelic drugs, for example. It would seem, in fact, to correspond to the transformative mechanism of the psychedelic experience. The goal ofthis study is to investigate the possibility of a mystical experience through hypnosis.


Description:

Anyone interested in taking part in the study will be contacted by telephone or e-mail and offered a face-to-face appointment to carry out the screening (T0). During the appointment, screening (cf. inclusion criteria) will be carried out, socio-demographic data (age, sex, education, nationality, history of hypnosis practice, etc.) and randomization will also take place at this time. At this time, the investigators will assess psychological flexibility and psychologigal well-being, and participants will do a cognitive flexibility task (T1). If people meet the inclusion criteria, the investigators will schedule an appointment for a session to take place roughly a week later. During this session, the investigators will start by reviewing beliefs about hypnosis, assessing participants' expectations of the study, their absorption and dissociation trait, their positive and negative affects and their anxiety. Next, the investigators will perform a 15-minute resting electroencephalographic (EEG) recording. We will then administer the Elkins Hypnotizability Scale. A 30-minute break will be taken. Next, the investigators willperform a hypnotic induction followed by a mystical experience suggestion for the experimental group. The control group will simply receive a reading of the mystical experience suggestion without hypnosis. The rest of the procedure is the same for both groups. EEG activity will be recorded during the mystical experience suggestion (± 15 minutes) in hypnosis and outside hypnosis (ordinary state of consciousness). Directly afterwards, participants will be asked to orally explain their subjective experience during the suggestion of mystical experience. Then the investigators will assess the positive and negative affect in addition to these outcomes: the mystical experience, the ego dissolution, the psychological flexibility, the cognitive flexibility, the altered state of consciousness, the near-death experience, alterness, absorption state, dissociation state, time perception (T2). Three months after receiving the experimental session, participants will be seen again for a follow-up session (T3). During this session, we will ask: "Since the experimental session, have you observed any changes in your behaviors, emotions and beliefs? If so, can you tell us about them?". The investigators will assess the positive and negative affects and psychological well-being.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date January 31, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - at least 18 years old - good comprehension of French Exclusion Criteria: - Psychiatric history - History of neurological disorder - Psychoactive medication - Addiction - Alcoholism

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Hypnosis
We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn & Evans, 2017).
Control
We will propose the neutral reading of a mystical expetience suggestion (based on Lynn & Evans, 2017).

Locations

Country Name City State
Belgium University of Liege Liège

Sponsors (1)

Lead Sponsor Collaborator
University of Liege

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Socio-demographics age, sex, éducation, nationality, prior practice of hypnosis or other non-ordinary states of consciousness, prior mystical experience. At screening
Other Psychiatric screening Psychiatric screening will be assessed with the Mini-International Neuropsychiatric Interview At screening
Other Beliefs about hypnosis Beliefs about hypnosis will be assessed with an open-ended question "What are your beliefs about hypnosis?" Before the procedure
Other Expectancies about the study Expectancies about the study will be assessed with an open-ended question "What are your expectancies about the study?" Before the procedure
Other Phenomenal control The phenomenal control will be assessed with the Phenomenological Control Scale. During the procedure
Other Positive and negative affects Positive and negative affects will be assessed with the Positive Affect and Negative Affect. Beforethe procedure, During the procedure, direcly after the procedure, and after 3 months
Other Absorption trait The absorption trait will be assessed with the Tellegen Absorption Scale which consists of 34 true/false items, aiming to measure the absorption of a person, meaning the disposition for having episodes of a deep involvement that engage all the subject's resources (perceptual, imaginative, and cognitive). The total score range is from 0 to 34. The higher the score, the more one has a high propensity for absorption. Before the procedure
Other Dissociation trait The dissociation trait will be assessed with the Dissociative Experience Scale. It is a self-reported questionnaire used to evaluate the presence, quantity, and type of dissociative experiences one might live in daily life. It consists of 28 items arranged on an analog scale (from 0 to 100% measuring the frequency of dissociative experiences), and the total score ranges from 0 to 100. There is a cutoff of 45 as a mean score to suggest a dissociative disorder. This questionnaire is not a diagnostic instrument; it is designed only for screening, but it can suggest that a specific clinical assessment is needed. Before the procedure
Other Anxiety state Anxiety will be assessed with a numerical rating scale. Before the procedure and during the procedure
Other Absorption state Absorption will be assessed with a numerical rating scale. During the procedure
Other Dissociation state Dissociation will be assessed with a numerical rating scale. During the procedure
Other Alertness Alertness will be assessed with a numerical rating scale. During the procedure
Other Time perception We will ask the participants how long they thought the intervention lasted. During the procedure
Other Near Death Experience The near death experience will be assessed with the The Near-Death Experience Content (NDE-C) Scale. During the procedure
Primary Mystical experience The 30-item revised Mystical Experience Questionnaire will assess the occurrence and intensity of mystical-type experiences. It is comprised of four factors: mysticality, positivity of mood, transcendence of time and space, and ineffability. A mystical experience is defined as having a score equal or above 60% on all factors. During the procedure
Primary Hypnotizability The susceptibility one has concerning hypnosis. Will be assessed with the Elkins Hypnotizability Scale. A score :
0-3 : low hypnotizability 4-7: medium hypnotizability 8-11 : high hypnotizability 12 : very high hypnotizability.
During the procedure
Secondary Ego Dissolution The Ego Dissolution Inventory will assess the occurrence of ego dissolution. During the procedure
Secondary Alteration of consciousness The Phenomenology of Consciousness Inventory will allow to empirically quantify the subjective experience in terms of pattern and intensity parameters. It is composed of 53 items consisting of 12 major dimensions (e.g., positive affect), and 14 minor dimensions (e.g., absorption) (annex). Graphs will be constructed to represent the intensity and pattern of relationships between pairs of dimensions. During the procedure
Secondary Psychological flexibility Multidimensional Psychological Flexibility Inventory. Before the procedure and direclty after the procedure
Secondary Cognitive flexibility Cognitive flexility will be assessed with the Test of Attentional Performance which is an informatized cognitive task. Before the procedure and direclty after the procedure
Secondary Psychological well-being Psychological well-being will be assessed with the Warwick-Edinburgh Mental Well-Being Scale Before the intervention and after 3 months
Secondary Modification of mood, cognition, emotion and behavior We will ask an open-ended question "Since the experimental session, have you observed any changes in your behaviors, emotions and beliefs? If so, can you tell us about them?". After 3 months
Secondary Phenomenal experience Phenomenal experience will be assessed by the recording of the narrative experience. During the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1